natgillin/translations-raw huggingface dataset:
This medicinal product is authorised in the Member States of EEA under the following names: Austria - Ciprofloxacin Hikma 200mg/100ml Infusionslösung Germany - Ciprofloxacin Hikma 200mg/100ml Lösung zur Intravenösen Anwendung Ireland - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion Italy - Ciprofloxacin Hikma 200mg/100ml Soluzione per Infusione Endovenosa United Kingdom - Ciprofloxacin Hikma 200mg/100ml Solution for Infusion The Netherlands - Ciprofloxacine Hikma 200mg/100ml Oplossing voor Intraveneuze Infusie 
Zdravilo je pridobilo dovoljenje za promet v državah članicah EGP pod naslednjimi imeni: Avstrija - Ciprofloxacin Hikma 200 mg/100 ml Infusionslösung Nemčija - Ciprofloxacin Hikma 200 mg/100 ml Lösung zur Intravenösen Anwendung Irska - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Italija - Ciprofloxacin Hikma 200 mg/100 ml Soluzione per Infusione Endovenosa Velika Britanija - Ciprofloxacin Hikma 200 mg/100 ml Solution for Infusion Nizozemska - Ciprofloxacine Hikma 200 mg/100 ml Oplossing voor Intraveneuze Infusie
They may take the form of local skin reactions, such as reddening of the skin, irritation or pain, which usually disappear quickly after termination of the infusion. 
Lahko v obliki lokalnih kožnih reakcij, kot je rdečica kože, draženje ali bolečina, ki ponavadi preneha kmalu po koncu infundiranja.
As with all other antibiotics, the patient should be monitored during therapy for the development of resistant strains of initially sensitive bacteria, especially P. aeruginosa and S. aureus (see the relevant statements in section 
Kot pri drugih antibiotikih je treba med zdravljenjem bolnika spremljati zaradi možnosti razvoja rezistentnih sevov sprva občutljivih bakterij, zlasti P. aeruginosa in S. aureus (glejte ustrezne navedbe v poglavju 5.1).
Any unused solution and the vial should be adequately disposed of in accordance with local requirements. 
Neuporabljeno raztopino in viale zavrzite v skladu z lokalnimi predpisi.
• If nevertheless complaints occur, such as fever, rash, itching, small red spots on the skin, you should consult your doctor since the treatment may need to be discontinued. 
• če se kljub temu pojavijo težave, kot so zvišana telesna temperatura, izpuščaj, srbenje ali majhne rdeče pike na koži, se morate takoj posvetovati z zdravnikom, ker bo morda treba prekiniti zdravljenje;
The treatment of acute pulmonary infections in children and adolescents with cystic fibrosis will take 10-14 days. 
Zdravljenje akutne okužbe pljuč pri otrocih in mladostnikih s cistično fibrozo traja 10-14 dni.
An extensive destruction of red blood cells (haemolytic reactions) may occur, causing anaemia. 
Lahko pride do obsežnega uničenja eritrocitov (hemolitične reakcije), ki povzroči anemijo.
The CHMP has recommended that the indication should be complicated urinary tract infections with a recommended dose of 200 - 400 mg twice daily. 
je CHMP je priporočil, naj se indikacija nanaša na zapletene okužbe sečil s priporočenim odmerkom 200 do 400 mg dvakrat dnevno.
Ciprofloxacin Hikma has minor or moderate influence on the ability to drive and use machines. 
Ciprofloxacin Hikma ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
It is also effective against Gram-positive organisms, such as staphylococci and streptococci. 
Učinkovit je tudi proti grampozitivnim organizmom, kot so stafilokoki in streptokoki.
• If exposure to sunlight or UV light is inevitable you should use sun cream to protect yourself. 
• če se sončni svetlobi ali UV-svetlobi ne morete izogniti, morate uporabiti kremo za zaščito proti soncu;
The peak plasma concentration is reached 0.5 - 2 hours after taking 50 - 1000 mg p.o. and varies from 0.3 - 5.9 mg/l. 
Največja koncentracija v plazmi je dosežena v 0,5-2 urah po peroralnem odmerku 50-1000 mg, spreminja pa se od 0,3 do 5,9 mg/l.
Ciprofloxacin and other fluoroquinolones may cause photosensibility. 
Ciprofloksacin in drugi fluorokinoloni lahko povzročijo fotosenzitivnost.
Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, tacrine, ropinirol, tizanidine). 
Ciprofloksacin zavira encim CYP1A2 in zato lahko poveča serumske koncentracije sočasno uporabljenih snovi, ki jih ta encim presnavlja (npr. teofilin, klozapin, takrin, ropinirol, tizanidin).
As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine. 
Zaradi svojega načina delovanja ciprofloksacin nima navzkrižne rezistence z drugimi pomembnimi, kemijsko različnimi skupinami zdravil, kot so betalaktamski antibiotiki, aminoglikozidi, tetraciklini, makrolidi in polipetidi, sulfonamidi, trimetoprim in nitrofurantoin.
The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3.4 and 6.9 hours. 
Razpolovni čas izločanja ciprofloksacina po enkratnem ali večkratnem peroralnem odmerku je med 3,4 in 6,9 ur.
Pharmacotherapeutic group: Antibacterial quinolones, ATC code: J01MA02 
Farmakoterapevtska skupina: kinolonske protimikrobne učinkovine, oznaka ATC: J01MA02
You should avoid long exposure to strong sunlight, sunlamps or other sources of UV radiation. 
Morate se izogibati dolgem izpostavljanju soncu, solariju ali drugim virom UV-sevanja;
Generally, acute and chronic infections (e.g. osteomyelitis and prostatitis, etc), where the causative organism is known to be sensitive to ciprofloxacin, should be treated for at least three days after the signs and symptoms of the infection have disappeared. 
Na splošno velja, da je treba akutne in kronične okužbe (npr. osteomielitis in prostatitis), pri katerih je znano, da je povzročitelj občutljiv na ciprofloksacin, zdraviti vsaj še tri dni po izginotju znakov in simptomov okužbe.
The bioavailability is lower if antacids that contain aluminium and/or magnesium hydroxide, and calcium and iron salts are used concomitantly. 
Biološka uporabnost je manjša ob sočasni uporabi antacidov, ki vsebujejo aluminijev in/ali magnezijev hidroksid, ter kalcijevih ali železovih soli.
The phototoxic, photomutagenic and photocarcinogenic potential of ciprofloxacin is comparable to that of other gyrase inhibitors. 
Fototoksični, fotomutageni in fotokarcinogeni potencial ciprofloksacina je primerljiv z drugimi zaviralci giraze.
When used simultaneously, ciprofloxacin may, in certain cases, increase the effect of glibenclamide (hypoglycaemia). 
Pri sočasni uporabi lahko ciprofloksacin v nekaterih primerih poveča učinek glibenklamida (hipoglikemija).
Animal trials have shown that the concurrent administration of very high doses of fluoroquinolones and certain NSAIDs (but not acetylsalicylic acid) may provoke convulsions. 
Preskušanja na živalih so pokazala, da lahko sočasna uporaba zelo velikih odmerkov fluorokinolonov in nekaterih nesteroidnih protivnetnih zdravil (vendar ne acetilsalicilne kisline) izzove konvulzije.
• If you experience these symptoms you should immediately consult your doctor and rest the respective leg. 
• če imate te simptome, se morate takoj posvetovati z zdravnikom, prizadete noge pa ne smete obremenjevati;
The applicant/MAH did not submit any clinical data to address the CHMP questions related to the risk/benefit of the proposed dose in UTIs and the maximum adult daily dose, as this application is a so called ″generic″ application (reference product/originator Ciproxin from Bayer). 
Vlagatelj/imetnik dovoljenja za promet ni predložil kliničnih podatkov, s katerimi bi odgovoril na vprašanja CHMP glede tveganj in koristi predlaganega odmerka za zdravljenje okužb sečil ter glede največjega odmerka za odrasle, saj gre pri tej vlogi za t.i. "generično" vlogo (referenčno zdravilo/ originator je Ciproxin družbe Bayer).
• complicated skin and soft tissue infections 
• zapletene okužbe kože in mehkih tkiv;
The dosage in children with impaired renal and/or hepatic function has not been investigated. 
Odmerjanja pri otrocih z okvarjenim delovanjem ledvic in/ali jeter niso raziskovali.
• If Ciprofloxacin Hikma and tizanidine (used to treat muscle spasms) are given at the same time. 
• če zdravilo Ciprofloxacin Hikma in tizanidin (uporablja se za zdravljenje mišičnih krčev) uporabljate sočasno.
It is contained in a type I, clear, colourless glass vial containing 100 ml solution. 
Pakirano je v vialo iz prozornega, brezbarvnega stekla vrste I, ki vsebuje 100 ml raztopine.
Management of patients with complicated urinary tract infections (UTIs) currently includes empirical treatment with a broad-spectrum antibiotic (fluoroquinolone), and potential subsequent treatment for 1014 days based on urine culture and sensitivity. 
Zdravljenje bolnikov z zapletenimi okužbami sečil (urinary tract infections, UTIs) trenutno obsega empirično zdravljenje z antibiotiki širokega spektra (fluorokinolon) in morebitno naknadno 10 do 14 dni trajajoče zdravljenje, odvisno od izsledkov na urinski kulturi in občutljivosti bolnika.
The ciprofloxacin level in the blood can be increased. 
Lahko se poveča raven ciprofloksacina v krvi;
In patients on haemodialysis or CAPD, the maximum daily intravenous dose is also 400 mg. On the dialysis days, the dose is given after the haemodialysis session. 
Pri bolnikih na hemodializi ali KAPD je dnevni intravenski odmerek prav tako 400 mg. Na dneve, ko je bolnik na dializi, se odmerek daje po hemodializi.
The bioavailability of ciprofloxacin after oral administration is between 70 % and 85 %. 
Biološka uporabnost ciprofloksacina po peroralni uporabi je med 70 in 85 %.
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillinresistant S. aureus, P. aeruginosa, E.coli and E. faecalis (see the sensitivity table). 
Razvoj rezistence za ciprofloksacin in druge fluorokinolone so opazili pri stafilokokih, zlasti pri S. aureus, P. aeruginosa, E.coli in E. faecalis, rezistentnimi na meticilin (glejte tabelo občutljivosti).
Please inform your doctor when under treatment with Ciprofloxacin Hikma as the result of this test may be false. 
Obvestite zdravnika, če se zdravite z zdravilom Ciprofloxacin Hikma, ker je rezultat tega preizkusa lahko napačen.
Important information about some of the ingredients of Ciprofloxacin Hikma If you are on a low-sodium diet, take into account that 100 ml of Ciprofloxacin Hikma contains 15.4 mmol (equivalent to 354 mg) sodium. 
Pomembne informacije o nekaterih sestavinah zdravila Ciprofloxacin Hikma Če ste na dieti z malo natrija, morate upoštevati, da 100 ml zdravila Ciprofloxacin Hikma vsebuje 15,4 mmol (kar ustreza 354 mg) natrija.
This product being a solution intended for intravenous infusion, should be restricted to the treatment of complicated UTI's. 
Ker je zdravilo raztopina za pripravo intravenske infuzije, bi njegovo uporabo morali omejiti na zdravljenje zapletenih okužb sečil.
If you or someone in your family suffers from this disease, you should consult your doctor. 
Če imate to bolezen ali če jo je imel kdo v vaši družini, se morate posvetovati z zdravnikom.
Photosensibility: 
Fotosenzitivnost:
Characteristics in patients: 
Lastnosti pri bolnikih:
The CHMP has therefore recommended the granting of the Marketing Authorisation(s) and the amendment of the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State. 
CHMP je zato priporočil odobritev dovoljenj(a) za promet z zdravilom in dopolnil Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo za referenčno državo članico.
Rare: syncope (fainting), vasodilation (heat stress). 
Redki: sinkopa (omedlevica), vazodilatacija (toplotni stres).
The elimination half-life of ciprofloxacin does not change with age. 
Razpolovni čas izločanja ciprofloksacina se s starostjo ne spreminja.
PHARMACEUTICAL FORM AND CONTENTS Solution for infusion. 
FARMACEVTSKA OBLIKA IN VSEBINA Raztopina za infundiranje
Ciprofloxacin Hikma cannot be mixed with solutions that are not stable at a pH of approximately 4. 
Zdravilo Ciprofloxacin Hikma se ne sme mešati z raztopinami, ki niso stabilne pri vrednosti pH približno 4.
Very rarely, a partial or total rupture (in particular of the Achilles tendon) has been reported, especially in elderly patients who were previously treated systemically with glucocorticoids. 
Zelo redko so poročali o celotni rupturi kite (predvsem ahilove kite), zlasti pri starejših bolnikih, ki so jih predhodno zdravili z glukokortikoidi.
Most frequent side effects affect the stomach and intestine, the nervous system and the skin and connective tissue. 
Najpogostejši neželeni učinki prizadenejo želodec in črevo, živčevje, kožo in vezivna tkiva.
Due to the increased risk of local reactions, higher intravenous doses in particular should only be administered via a large vein or a central line. 
Zaradi povečanega tveganja za pojav lokalnih reakcij je treba večje intravenske odmerke dajati z venskim ali centralnim katetrom.
There are insufficient data available with regard to the use of ciprofloxacin in children and adolescents. 
Podatki o uporabi ciprofloksacina pri otrocih in mladostnikih so nezadostni.
However, like a number of other quinolones ciprofloxacin is phototoxic in animals in exposure values relevant to humans. 
Vendar je tako kot veliko drugih kinolonov fototoksičen pri živalih pri izpostavljenosti, ki je primerljiva z izpostavljenostjo pri človeku.
In juvenile and prenatal animals exposed to quinolones effects on immature cartilage have been observed (see section 5.3). 
Pri neodraslih in prenatalnih živalih, izpostavljenih kinolonom, so opazili učinke na hrustanec (glejte poglavje 5.3).
Impaired hepatic function: In case of impaired hepatic function it is not necessary to adjust the dosage. 
Okvarjeno delovanje jeter: Pri okvarjenem delovanju jeter odmerka ni treba prilagajati.
Oral anticoagulants (e.g. warfarin) 
Peroralni antikoagulansi (npr. varfarin)
Using other medicines If Ciprofloxacin Hikma and one of the following medicines are given at the same time, special care should be taken: 
Uporaba drugih zdravil Če zdravilo Ciprofloxacin Hikma jemljete skupaj z enim izmed naslednjih zdravil, morate biti posebno previdni:
When during or after the treatment with ciprofloxacin or another fluoroquinolone severe and persistent diarrhoea occurs, pseudomembranous colitis must be taken into account (life-threatening with possibly fatal outcome). 
Kadar se pri zdravljenju s ciprofloksacinom ali drugimi fluorokinoloni, ali po njem, pojavi huda persistentna driska, je treba upoštevati možnost, da gre za psevdomembranski kolitis (smrtno nevaren z možnim smrtnim izidom).
If you use one of these medicines together with ciprofloxacin you will be monitored for signs of overdose. 
Če katero koli od teh zdravil jemljete skupaj s ciprofloksacinom, vas bodo opazovali zaradi znakov prevelikega odmerjanja.
• convulsions (seizures), epilepsy or another brain disease, for example decreased blood circulation in the brain, stroke or increased sensitivity to convulsions, since possible side effects of ciprofloxacin may cause damage to the brain. 
• konvulzije (epileptične napade), epilepsijo ali drugo bolezen možganov, na primer zmanjšan pretok krvi v možganih, možgansko kap ali povečano občutljivost za epileptične napade, ker možni neželeni učinki ciprofloksacina lahko povzročijo poškodbe možganov;
These are set out in Annex III for Ciprofloxacin and associated names (see Annex I). 
Ta so natančno določena v Dodatku III za zdravilo Ciprofloxacin in z njim povezana imena (oglejte si Dodatek I).
Ciprofloxacin Hikma is an antibiotic. 
Zdravilo Ciprofloxacin Hikma je antibiotik.
• significant renal impairment. 
• huda ledvična okvara.
A larger number of metabolites after oral administration indicates some degree of first-pass metabolism, mainly forming sulphociprofloxacin. 
Večje število presnovkov po peroralni uporabi kaže na določeno stopnjo presnove prvega prehoda skozi jetra, pri čem nastaja predvsem sulfociprofloksacin.
The pharmacokinetics of ciprofloxacin in children with cystic fibrosis differs from that in children without cystic fibrosis, and dosing recommendations are only applicable for children with cystic fibrosis. 
Pri otrocih s cistično fibrozo se farmakokinetika ciprofloksacina razlikuje od farmakokinetike pri otrocih brez cistične fibroze, režim odmerjanja pa velja samo za otroke s cistično fibrozo.
OTHER SPECIAL WARNING(S), IF NECESSARY See enclosed leaflet. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Glejte priloženo navodilo za uporabo.
Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome), petechia. 
Zelo redki: nodozni eritem, multiformni eritem (manjši), Stevens-Johnsonov sindrom, epidermalna nekroliza (Lyellov sindrom), petehija.
In very rare cases ventricular arrhythmia, QT interval prolongation and torsades de pointes have been reported. 
V zelo redkih primerih so poročali o ventrikularni aritmiji, podaljšanju intervala QT in aritmiji "torsades de pointes".
Very rare: asthenia, a transient impairment of kidney function to transient renal failure, photosensitivity (see Section 4.4). 
Zelo redki: astenija, prehodna okvara delovanja ledvic do prehodne ledvične odpovedi, fotosenzitivnost (glejte poglavje 4.4).
• children and growing adolescents except for the treatment of acute pulmonary exacerbations of cystic fibrosis in children aged 5 to 17 years. 
• otrocih in odraščajočih mladostnikih, razen za zdravljenje akutnih pulmonalnih eksacerbacij cistične fibroze pri otrocih, starih od 5 do 17 let;
Since ciprofloxacin is associated with very rare cases of QT prolongation (see section 4.8) caution should be exercised when treating patients at risk for torsade de pointes arrhythmia. 
Ciprofloksacin je povezan z zelo redkimi primeri podaljšanja intervala QT (glejte poglavje 4.8), zato je pri zdravljenju bolnikov s tveganjem za aritmijo "torsade de pointes", potrebna previdnost.
This applies to gall, kidney, gall bladder and liver tissue. 
To velja za žolč, ledvica, žolčnik in jetrno tkivo.
• If you have known allergic reaction (hypersensitivity) to ciprofloxacin or any of the other ingredients of Ciprofloxacin Hikma or other medicines of the quinolone type 
• če imate znano alergijsko reakcijo na (če ste preobčutljivi za) ciprofloksacin ali katero koli sestavino zdravila Ciprofloxacin Hikma ali druga kinolonska zdravila;
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin. 
O neželenih reakcijah so poročali pri 5-14 % bolnikov, ki so prejemali ciprofloksacin.
Patients with a family history of or actual defects in glucose-6-phosphate dehydrogenase activity are prone to haemolytic reactions with quinolones, and so ciprofloxacin should be used with caution in these patients. 
Bolniki z okvaro delovanja glukoze-6-fosfat dehidrogenaze v družinski anamnezi so nagnjeni k hemolitičnim reakcijam na kinolone, zato je treba ciprofloksacin pri njih uporabljati previdno.
Ciprofloxacin has a rapid bactericidal effect, both in the growth phase and in the rest phase. 
Ciprofloksacin ima hiter baktericiden učinek, v fazi razmnoževanja bakterij in tudi v fazi mirovanja.
administration of 200 mg the plasma concentration is still higher than the MIC values of the majority of clinically relevant pathogens (approximately 0.1 µg/ml). 
Dvanajst ur po intravenskem dajanju odmerka 200 mg je koncentracija v plazmi še vedno večja od najmanjše zaviralne koncentracije večine klinično pomembnih povzročiteljev (približno 0,1 µg/ml).
In case of very severe infections the dose can be increased up to a maximum daily dose of 1200 mg (400 mg thrice daily). 
Pri zelo hudih okužbah je lahko odmerek poveča na največji dnevni odmerek 1200 mg (400 mg trikrat na dan).
Signs of these reactions are: a sharp drop in blood pressure, paleness, restlessness, weak/rapid pulse, clammy skin, dizziness. 
Znaki teh reakcij so hitro zmanjšanje krvnega tlaka, bledica, nemir, šibek/hiter srčni utrip, vlažna koža, omotica.
• life-threatening increase heart rate (torsade de pointes). 
• smrtno nevarno povečanje srčnega utripa (aritmija "torsade de pointes").
Very rare: hepatitis, liver cell necrosis (very rarely resulting in life-threatening liver function failure). 
Zelo redki: hepatitis, nekroza jetrnih celic (zelo redko povzroči smrtno nevarno odpoved delovanja jeter).
Due to the risk of arthropathy and other potentially severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 4.3). 
Zaradi tveganja za artropatijo in druge hude toksične učinke na novorojenca je ciprofloksacin med dojenjem kontraindiciran (glejte poglavje 4.3).
Especially patients undergoing long-term treatment (e.g. in cystic fibrosis, osteomyelitis), or patients who are extremely susceptible to infections (e.g. in selective prophylaxis in certain groups of neutropenic patients, artificial ventilation) show the highest risk. 
Največje tveganje kažejo predvsem bolniki, pri katerih je zdravljenje dolgotrajno (npr. pri cistični fibrozi in osteomielitisu), ali bolnikih, ki so zelo dovzetni za okužbe (npr. pri selektivni profilaksi pri določeni skupini nevtropeničnih bolnikov, bolnikih na umetni ventilaciji).
Ciprofloxacin Hikma should be administered via a short-term intravenous infusion (infusion into a vein) over 30 to 60 minutes. 
Zdravilo Ciprofloxacin Hikma je treba dajati s kratkotrajnim intravenskim infundiranjem (infundiranjem v veno), ki traja 30 do 60 minut.
Within the class of quinolones cross-resistance has been observed. 
Navzkrižno rezistenco so opazili znotraj razreda kinolonov.
Following concomitant administration of ciprofloxacin and cyclosporine a transient increase of the serum creatinine concentration has been observed in separate cases. 
Po sočasni uporabi ciprofloksacina in ciklosporina so v posameznih primerih opazili prehodno povečanje koncentracije kreatinina v serumu.
• oral anticoagulants (used to prevent blood from clotting, e.g. warfarin). 
• peroralni antikoagulansi (uporabljajo se za preprečevanje strjevanja krvi, npr. varfarin).
The interaction between theophylline and ciprofloxacin is potentially life-threatening. 
Interakcija med teofilinom in ciprofloksacinom je lahko smrtno nevarna.
The reconstituted solution is clear. 
Rekonstituirana raztopina je bistra.
Central nervous system: 
Osrednje živčevje:
In addition the maximum daily dose for the use of ciprofloxacin should be 400 mg three times daily. 
Poleg tega bi moral največji dnevni odmerek ciprofloksacina znašati 400 mg trikrat dnevno.
Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin. 
Ciprofloksacin, kot drugi kinoloni, lahko okrepijo učinek derivatov kumarina, vključno z varfarinom.
Animal experiments have shown that ciprofloxacin passes the placenta and is excreted in breast milk. 
Preizkusi na živalih so pokazali, da ciprofloksacin prehaja v placento in se izloča v materinem mleku.
Anaphylactic/anaphylactoid reactions can in very rare cases develop into life-threatening shock, sometimes even after the first administration of ciprofloxacin. 
Anafilaktične/anafilaktoidne reakcije lahko v redkih primerih povzročijo smrtno nevarni šok, včasih že po prvem odmerku ciprofloksacina.
Very rare in less than 1 in 10,000 patients, including isolated reports 
Zelo redki pri manj kot 1 bolniku od 10.000, vključno s posameznimi primeri
Hydrochloric acid (E 507) for pH adjustment Water for injections 
Klorovodikova kislina (E 507) za uravnavanje pH Voda za injekcije
• glibenclamide (used to treat diabetes). 
• glibenklamid (uporablja se za zdravljenje sladkorne bolezni).
There is a linear correlation between dose on the one hand and plasma concentration and AUC on the other. 
Med odmerkom na eni strani in koncentracijo v plazmi ter vrednostjo AUC na drugi obstaja linearna korelacija.
Use only clear solutions and undamaged containers. 
Uporabite samo bistro raztopino in nepoškodovano ovojnino.
In that case the ciprofloxacin therapy must immediately be discontinued and an appropriate treatment initiated. 
V takem primeru je treba zdravljenje s ciprofloksacinom takoj prekiniti in začeti ustrezno zdravljenje.